Amgen, Merck Team On Cancer Immmunotherapy Studies

Thousand Oaks-based Amgen and fellow biopharmaceuticals giant Merck said today that they are in a cancer immunotherapy collaboration, to support a Phase 1b/3 study. The two said the study includes both Amgen's BLINCYTO (blinatumomab) product and Merck's EKYTRUDA (pemblizumab) therapy, for treating non-Hodgkin lymphoma. The two also said they will collaborate on a Phase 1/2 study of Amgen's AMG 820 antibody to treat advanced solid tumors, including non-small cell lung, colorectal and pancreatic cancers. Financial details of the collaboration were not annoucned.